| Growing demand for advanced AI as drug development increasingly depends on large-scale data processing and iterative validation
| Generative AI–driven drug discovery market projected to grow rapidly, reaching USD 2.8 billion by 2034
| JNPMEDI, JW Pharmaceutical, Hanmi Pharmaceutical, and Lunit draw attention as companies with strong AI-driven drug development capabilities
Artificial intelligence is reshaping the pharmaceutical and biotechnology industry, which has long struggled with high costs and low development efficiency. Drug development depends on large-scale data processing and repeated validation across discovery, preclinical, clinical and safety stages, fueling strong demand for advanced AI technologies.
The shift is accelerating as the U.S. Food and Drug Administration moves toward phasing out mandatory animal testing, increasing interest in AI-driven drug development platforms and companies with differentiated capabilities. According to the Korea Health Industry Development Institute, the generative AI–based drug discovery market is projected to grow from $250 million in 2024 to $2.8 billion by 2034.
JNPMEDI is driving digital transformation through its AI-powered clinical trial data management platform, Maven Clinical Cloud, and its pharmacovigilance solution, Maven Safety. Maven Clinical Cloud detects errors and abnormal patterns in clinical data, provides real-time guidance to investigators and converts data into global standards such as CDISC SDTM and ADaM to support submissions to major regulators including the FDA, the European Medicines Agency and Korea’s Ministry of Food and Drug Safety. Maven Safety, an international standards-based safety data management platform, supports secure data exchange using the AS2 protocol and provides strong traceability and data integrity.
NAVER recently made a strategic investment in JNPMEDI and signed an agreement to pursue joint global expansion in digital healthcare.
JW Pharmaceutical said a metabolic disease drug candidate discovered using its AI-driven platform JWave has been selected for Korea’s 2025 National New Drug Development Project. The company said JWave applies more than 20 AI models to large biological and chemical datasets to accelerate hit identification and lead optimization.
Hanmi Pharmaceutical said it has been selected as a participating research organization for the government-led “2025 K-AI Drug Development Preclinical and Clinical Model Development Project,” which aims to develop AI software for reverse translational research that feeds clinical data back into preclinical stages.
Lunit said it has signed a collaboration agreement with Daiichi Sankyo to apply its AI biomarker platform, Lunit SCOPE, to two oncology pipelines under development. The collaboration includes AI-based biomarker discovery, optimization of translational and clinical studies, and precise patient stratification.
| Growing demand for advanced AI as drug development increasingly depends on large-scale data processing and iterative validation
| Generative AI–driven drug discovery market projected to grow rapidly, reaching USD 2.8 billion by 2034
| JNPMEDI, JW Pharmaceutical, Hanmi Pharmaceutical, and Lunit draw attention as companies with strong AI-driven drug development capabilities
Artificial intelligence is reshaping the pharmaceutical and biotechnology industry, which has long struggled with high costs and low development efficiency. Drug development depends on large-scale data processing and repeated validation across discovery, preclinical, clinical and safety stages, fueling strong demand for advanced AI technologies.
The shift is accelerating as the U.S. Food and Drug Administration moves toward phasing out mandatory animal testing, increasing interest in AI-driven drug development platforms and companies with differentiated capabilities. According to the Korea Health Industry Development Institute, the generative AI–based drug discovery market is projected to grow from $250 million in 2024 to $2.8 billion by 2034.
JNPMEDI is driving digital transformation through its AI-powered clinical trial data management platform, Maven Clinical Cloud, and its pharmacovigilance solution, Maven Safety. Maven Clinical Cloud detects errors and abnormal patterns in clinical data, provides real-time guidance to investigators and converts data into global standards such as CDISC SDTM and ADaM to support submissions to major regulators including the FDA, the European Medicines Agency and Korea’s Ministry of Food and Drug Safety. Maven Safety, an international standards-based safety data management platform, supports secure data exchange using the AS2 protocol and provides strong traceability and data integrity.
NAVER recently made a strategic investment in JNPMEDI and signed an agreement to pursue joint global expansion in digital healthcare.
JW Pharmaceutical said a metabolic disease drug candidate discovered using its AI-driven platform JWave has been selected for Korea’s 2025 National New Drug Development Project. The company said JWave applies more than 20 AI models to large biological and chemical datasets to accelerate hit identification and lead optimization.
Hanmi Pharmaceutical said it has been selected as a participating research organization for the government-led “2025 K-AI Drug Development Preclinical and Clinical Model Development Project,” which aims to develop AI software for reverse translational research that feeds clinical data back into preclinical stages.
Lunit said it has signed a collaboration agreement with Daiichi Sankyo to apply its AI biomarker platform, Lunit SCOPE, to two oncology pipelines under development. The collaboration includes AI-based biomarker discovery, optimization of translational and clinical studies, and precise patient stratification.